Loren Data's SAM Daily™

FBO DAILY ISSUE OF JULY 01, 2011 FBO #3506
SOURCES SOUGHT

B -- Whole Exome Sequencing of Genes Underlying Subclinical Atherosclerosis

Notice Date

6/29/2011
 

Notice Type

Sources Sought
 

NAICS

541712 — Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
 

ZIP Code

20892-7902
 

Solicitation Number

NHLBI-CSB-(HL)-2011-232-DDC
 

Archive Date

7/28/2011
 

Point of Contact

Deborah - Coulter, Phone: (301) 435-0368
 

E-Mail Address

dc143b@nih.gov
(dc143b@nih.gov)
 

Small Business Set-Aside

N/A
 

Description

Title: Whole Exome Sequencing of Genes Underlying Subclinical Atherosclerosis This is a Sources Sought Notice (SS). This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of ALL qualified sources that are interested in, and capable of, providing the Whole Exome Sequencing of Genes Underlying Subclinical Atherosclerosis services. The National Heart, Lung, and Blood Institute (NHLBI) does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this Sources Sought notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this Sources Sought notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The NHLBI is seeking capability statements from all eligible business' under the North American Industry Classification System (NAICS) code 541712 with a size standard of 500 employees. All eligible business' responding to this Sources Sought Announcement must have the capabilities to provide the below services upon receipt of order. Interested parties are expected to review this notice to familiarize yourself with the requirements of this project; failure to do so will be at your firm's own risk. Background Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study (FHS) -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute; NHLBI) -- embarked on an ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. Purpose and Objectives: The objective of the FHS has been to identify the common factors or characteristics that contribute to CVD by following its development over time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The FHS continues to make important scientific contributions by enhancing its research capabilities and capitalizing on its inherent resources. New diagnostic technologies, such as carotid-artery ultrasound to measure as carotid intimal medial thickness (IMT) and plaque, multidetector computerized tomography of the coronary arteries to measure coronary artery calcium (CAC) and aortic calcium (AC) have been completed in two serial examination cycles of the FHS. While pursuing the study's established research goals, the NHLBI and the Framingham investigators have expanded their research into other areas such as the role of genetic factors in CVD. Framingham investigators also collaborate with leading researchers from around the country and throughout the world on genetics and genomics projects in subclinical atherosclerosis, myocardial infarction, stroke and dementia, as well as risk factors for these conditions, including hypertension, hyperlipidemia and diabetes. In the largest genomewide association studies (GWAS) for subclinical atherosclerosis to date, our group has described for the first time common genetic variants (single nucleotide polymorphisms, or SNPs) in multiple genes underlying carotid IMT/plaque and CAC. Several of these SNPs are concordant with loci underlying myocardial infarction and lipids. We hypothesize that a substantial proportion of the unknown heritability of clinical CVD and subclinical atherosclerosis and its risk factors is determined by low frequency and rare ("private") genetic variants. Sequencing of the entire exome (exomewide sequencing) using next-generation DNA sequencing methodology is now underway to discover causal variants underlying clinically apparent CVD and CVD risk factors in research participants at the extremes of these conditions; further, exomewide studies are underway in families with rare, highly penetrant conditions. However, no exomewide studies are yet planned to discover the role of lower frequency variants in subclinical atherosclerosis or in collections of multiple families. This project seeks to identify the low frequency and rare genetic sequence variations underlying subclinical atherosclerosis in families drawn from the FHS. The presence and quantity of subclinical atherosclerosis has been determined by carotid ultrasonography (as IMT and plaque) in the Offspring cohort, and by computed tomography testing (as CAC and AC) in the Offspring and Gen3 cohorts. Increasing levels of carotid IMT/plaque and CAC each independently predict the incidence of myocardial infarction and stroke, leading causes of death and morbidity in men and women. We propose to conduct exomewide sequencing in individuals from multiple families harboring participants with evidence of high levels of subclinical atherosclerosis. Exome sequence data from the Broad Institute, as well as GWAS data, are available for secondary analyses in dbGaP to Dr. O'Donnell through approved research proposals for up to 1000 FHS participants as well as several thousand additional participants from other NHLBI cohorts. The Broad resequencing facility will conduct sequencing of DNA in at least 200 individuals and up to 300 total individuals. Sequencing will be performed using 1 mcg of DNA, which provides enough material for validation genotyping and repeat analysis of any failed samples. Sequencing will be conducted using next-generation sequencing protocols that have been refined in other large exome sequencing projects (Illumina paired-end resequencing). Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically (via email) to Deborah Coulter, Contract Specialist, at coulterd@nhlbi.nih.gov in either MS Word or Adobe Portable Document Format (PDF), by July 13, 2011, 9:00 AM, EST. All responses must be received by the specified due date and time in order to be considered.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-232-DDC/listing.html)
 

Place of Performance

Address: Broad Institute, Seven Cambridge Center, Cambridge, Massachusetts, 02142, United States

Zip Code: 02142
 

Record

SN02486065-W 20110701/110629235403-529a12b27cd584790bdde3a0a9c13968 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |